U.S., Oct. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07218315) titled 'Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma' on Oct. 16.
Brief Summary: This study is to evaluate the effectiveness of nsPFA in treating papillary thyroid microcarcinoma. T
Study Start Date: April 30, 2026
Study Type: INTERVENTIONAL
Condition:
Thyroid Carcinoma
Intervention:
DEVICE: CellFX nsPFA Percutaneous Electrode System
Patients will undergo thyroid ablation with the CellFX nsPFA system, an outpatient procedure under local anesthesia, or intravenous sedation.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: M.D. Anderson Cancer Center
Published by HT Digital Content Services...